PHARMACOVIGILANCE

Edited by

RONALD D. MANN
ELIZABETH B. ANDREWS

JOHN WILEY & SONS, LTD
PHARMACOVIGILANCE
PHARMACOVIGILANCE

Edited by

RONALD D. MANN

ELIZABETH B. ANDREWS

JOHN WILEY & SONS, LTD
## Contents

List of Contributors ................................................................. ix

Preface .................................................................................. xvii

Foreword .............................................................................. xix

**PART I. BASIS OF PHARMACOVIGILANCE** ........................................... 1

1. **Introduction** ..................................................................... 3  
   Ronald D. Mann and Elizabeth B. Andrews

2. **Legal Basis—EU** ............................................................. 11  
   Nicholas Macfarlane, Gabrielle Turner, Caroline Moore, Christoph Hiltl, Paule Drouault-Gardrat and Paolo Ricci

3. **Legal Basis—US** ............................................................. 27  
   Robert P. Brady and Mark D. Learn

4. **Ethical Oversight, Consent, and Confidentiality** ............... 37  
   Donna A. Boswell and Elizabeth B. Andrews

5. **Pre-clinical Safety Evaluation** ............................................. 51  
   Norma Kellett, Stuart J. Mair and Walter S. Nimmo

6. **Metabolic Mechanisms** ................................................... 57  
   Munir Pirmohamed and B. Kevin Park

7. **Drugs and the Elderly** ..................................................... 77  
   Una Martin and Charles George

8. **Natural History** ............................................................. 97  
   Paul E. Stang

9. **Responding to Signals** .................................................... 105  
   Patrick C. Waller and Peter Arlett

10. **Micturin and Torsades de Pointes** .................................... 129  
    Richard N. Wild

11. **Withdrawal of Terodiline: A Tale of Two Toxicities** ............ 135  
    Rashmi R. Shah

12. **Nomifensine and Haemolytic Anaemia** ............................ 155  
    Peter D. Stonier and J. Guy Edwards
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>WHO Programme—Global Monitoring</td>
<td>I. Ralph Edwards and Sten Olsson</td>
</tr>
<tr>
<td>14</td>
<td>Regulatory Pharmacovigilance in the EU</td>
<td>Patrick C. Waller and Priya Bahri</td>
</tr>
<tr>
<td>15</td>
<td>Spontaneous Reporting—UK</td>
<td>Sarah Davis and June M. Raine</td>
</tr>
<tr>
<td>16</td>
<td>Spontaneous Reporting—France</td>
<td>Nicholas Moore, Carmen Krefl-Jais and Alban Dahmani</td>
</tr>
<tr>
<td>17</td>
<td>Spontaneous Reporting—USA</td>
<td>David J. Graham, Syed R. Ahmad and Toni Piazza-Hepp</td>
</tr>
<tr>
<td>18</td>
<td>Algorithms</td>
<td>John A. Clark</td>
</tr>
<tr>
<td>19</td>
<td>Overview—Spontaneous Signalling</td>
<td>John A. Clark, Stephen L. Klinewicz and Paul E. Stang</td>
</tr>
<tr>
<td>20</td>
<td>Statistical Methods of Signal Detection</td>
<td>John A. Clark</td>
</tr>
<tr>
<td>21</td>
<td>Statistical Methods of Evaluating Pharmacovigilance Data</td>
<td>Bernard Bégaud</td>
</tr>
<tr>
<td>22</td>
<td>Data Mining</td>
<td>I. Ralph Edwards, Marie Lindquist, Andrew Bate and Roland Orre</td>
</tr>
<tr>
<td>23</td>
<td>Epidemiology of Adverse Events Associated with Epilepsy and Use of Lamotrigine</td>
<td>Patricia Tennis</td>
</tr>
<tr>
<td>24</td>
<td>Pharmacovigilance in the Netherlands</td>
<td>A.C. van Groothest and E.P. van Puijenbroek</td>
</tr>
<tr>
<td>25</td>
<td>CIOMS Working Groups and their Contribution to Pharmacovigilance</td>
<td>Sue Roden</td>
</tr>
<tr>
<td>26</td>
<td>PEM in the UK</td>
<td>Saad A.W. Shakir</td>
</tr>
<tr>
<td>27</td>
<td>PEM in New Zealand</td>
<td>David M. Coulter</td>
</tr>
<tr>
<td>28</td>
<td>MEMO in the UK</td>
<td>Douglas Steinke, Josie M.M. Evans and Thomas M. Macdonald</td>
</tr>
<tr>
<td>29</td>
<td>GPRD in the UK</td>
<td>Louise Wood</td>
</tr>
<tr>
<td>30</td>
<td>Overview of North American Databases</td>
<td>Brian L. Strom and Judith L. Kinman</td>
</tr>
<tr>
<td>31</td>
<td>Pharmacovigilance in the HMO Research Network</td>
<td>Richard Platt et al.</td>
</tr>
<tr>
<td>32</td>
<td>Other databases in Europe</td>
<td>Miriam C.J.M. Sturkenboom</td>
</tr>
<tr>
<td>33</td>
<td>Surveillance for Medical Devices—USA</td>
<td>Thomas P. Gross and Larry G. Kessler</td>
</tr>
</tbody>
</table>
### CONTENTS

#### PART III. PHARMACOVIGILANCE AND SELECTED SYSTEM ORGAN CLASSES

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>34.</td>
<td><strong>Dermatological ADRs</strong></td>
<td>Laurence Valeyrie and Jean-Claude Roujeau</td>
</tr>
<tr>
<td>35.</td>
<td><strong>Gastrointestinal ADRs</strong></td>
<td>John R. Wood and Graham A. Pipkin</td>
</tr>
<tr>
<td>36.</td>
<td><strong>Haematological ADRs</strong></td>
<td>Sarah Davis and Ronald D. Mann</td>
</tr>
<tr>
<td>37.</td>
<td><strong>Hepatic Adverse Drug Reactions</strong></td>
<td>Guruprasad P. Aithal and Christopher P. Day</td>
</tr>
<tr>
<td>38.</td>
<td><strong>Ocular ADRs</strong></td>
<td>F.W. Fraunfelder and F.T. Fraunfelder</td>
</tr>
<tr>
<td>39.</td>
<td><strong>Drug Safety in Pregnancy</strong></td>
<td>Christina D. Chambers and Elizabeth B. Andrews</td>
</tr>
<tr>
<td>40.</td>
<td><strong>ADRs and Drug Safety 1999–2000</strong></td>
<td>Pauline Curel and Rosie Stather</td>
</tr>
</tbody>
</table>

#### PART IV. LESSONS AND DIRECTIONS

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>41.</td>
<td><strong>Teaching Pharmacovigilance</strong></td>
<td>Ronald Meyboom, Sten Olsson and Margaret Thorogood</td>
</tr>
<tr>
<td>42.</td>
<td><strong>Medical Errors and Lessons from Drug-Related Deaths</strong></td>
<td>Richard E. Ferner and R.M. Whittington</td>
</tr>
<tr>
<td>43.</td>
<td><strong>Pharmacogenetics and the Genetic Basis of ADRs</strong></td>
<td>Penelope K. Manasco, Patricia Rieser, Gaile Renegar and Michael Mosteller</td>
</tr>
<tr>
<td>44.</td>
<td><strong>Keynote Clinical Lessons from Pharmacovigilance</strong></td>
<td>David H. Lawson</td>
</tr>
</tbody>
</table>

Index | 545
Contributors

SYED R. AHMAD, MB, BS, MPH
Medical Epidemiologist, Division of Drug Risk Evaluation, Office of Drug Safety, Center for Drug Evaluation and Research, US Food and Drug Administration, 5600 Fishers Lane, HFD-400, Rm 15B-32, Rockville, MD 20857, USA, AHMADS@cdер.fda.gov

GURUPRASAD P. AITHAL, MD, MRCP, PhD
Consultant Hepatobiliary Physician, Queen’s Medical Centre, University Hospital, D Floor, South Block, Nottingham NG7 2UH, UK, guru.aithal@mail.qmcuh-tr.trent.nhs.uk

SUSAN E. ANDRADE, ScD
Senior Research Associate, Meyers Primary Care Institute, Fallon Healthcare System, and University of Massachusetts, Worcester, MA 01605, USA, susaneandrade@aol.com

ELIZABETH B. ANDREWS, MPH, PhD
Vice President, RTI Health Solutions, Research Triangle Institute, 3040 Cornwallis Road, PO Box 12194, Research Triangle Park, NC 27709-2194, USA, Adjunct Associate Professor, School of Public Health and School of Pharmacy, University of North Carolina at Chapel Hill, NC, USA, eandrews@rti.org

PETER ARLETT, BSc, MBBS, MRCP
Senior Medical Assessor and CPMP Delegate, Post-Licensing Division, Medicines Control Agency, Market Towers, 1 Nine Elms Lane, London SW8 5NQ, UK, peter.arlett@mea.gsi.gov.uk

PRIYA BAHRI, PhD
Scientific Administrator, Sector Pharmacovigilance and Post-Authorisation Safety and Efficacy of Human Medicines, European Agency for the Evaluation of Medicinal Products (EMEA), 7 Westferry Circus, London E14, 4HB, UK, priya.bahri@emea.eu.int

ANDREW BATE, MA
Programme Leader, Signal Research Methodology, Uppsala Monitoring Centre, Stora Torget 3, 753 20 Uppsala, Sweden, andrew.bate@who-umc.org

BERNARD BÉGAUD, MD
Professor of Pharmacology, Département de Pharmacologie Clinique—Unité de Pharmaco-épidémiologie, ARME-Pharmacovigilance, Université Victor Segalen, 33076 Bordeaux, France, Bernard.Begaud@pharmaco.u-bordeaux2.fr

DONNA A. BOSWELL, JD, PhD
Partner, Hogan & Hartson, L.L.P., Columbia Square, 555 Thirteenth Street, NW, Washington, DC 20004-1109, USA, daboswell@hhlaw.com
Contributors

ROBERT P. BRADY, Esq.
Partner, Hogan & Hartson, L.L.P., Columbia Square, 555 Thirteenth Street, NW, Washington, DC 20004-1109, USA, rpbrady@hhlaw.com

CHRISTINA D. CHAMBERS, MPH, PhD
Assistant Professor of Pediatrics, Department of Pediatrics, UCSD Medical Center MC8446, 200 W Arbor Drive, San Diego, CA 92103, USA, chchambers@ucsd.edu

K. ARNOLD CHAN, MD, ScD
Assistant Professor, Department of Epidemiology, Harvard School of Public Health, Boston, MA 02215, USA, kchan@hsph.harvard.edu

JOHN A. CLARK, MD, MSPH
Vice President, Safety Services, Galt Associates, Inc., 21240 Ridgetop Circle, Ste 140, Sterling, VA 20166, USA, johnc@galt-assoc.com

DAVID M. COULTER, MB, ChB (NZ), DTM&H (Sydney)
Head, Centre for Adverse Drug Reactions Monitoring, Director, Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, PO Box 913, Dunedin, New Zealand, david.coulter@stonebow.otago.ac.nz

PAULINE CUREL, MPS
Team Leader, Drug Information Pharmacists, Clineanswers, Clear Centre, Smales Farm Office Park, PO Box 33-1548, Takapuna, Auckland 1332, New Zealand, pauline.curel@clineanswers.com

ALBAN DAHNANI, PharmD
Assistant to the Head of the Pharmacovigilance Unit, Agence Francaise de Sécurité Sanitaire des Produits de Santé (AFSSAPS), 143/147 Bd Anatole, France 93 285 St Denis, France, alban.dahnani@afssaps.sante.fr

ROBERT L. DAVIS, MD, MPH
Associate Professor, Department of Pediatrics and Epidemiology, University of Washington, and Group Health Cooperative Center for Health Studies, Seattle, WA 98101, USA, rdavis@u.washington.edu

SARAH DAVIS, BSc (Hons), PhD
Scientific Assessor, Pharmacovigilance Group, Post-Licensing Division, Medicines Control Agency, Market Towers, 1 Nine Elms Lane, London SW8 5NQ, UK, sarah.davis@mca.gsi.gov.uk

CHRISTOPHER P. DAY, FRCP, MD, PhD
Professor of Liver Medicine and Honorary Consultant Hepatologist, Centre for Liver Research, The Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, UK, c.p.day@ncl.ac.uk

FRANK DESTEFANO, MD, PhD
Project Director, Vaccine Safety Datalink, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA, fxd1@cdc.gov

PAULE DROUAULT-GARDRAT, LL.M, CEIPI, Avocat
Pharmacist, Lovells, 37 Avenue Pierre-1er-De Serbie, 75008 Paris, France, pdg@lovells.com

J. GUY EDWARDS, MB, BCh, FRCPsych, DPM
Visiting Professor, Khon Kaen University, Khon Kaen and Prince of Songkla University, Hat Yai, Thailand

I. RALPH EDWARDS, MB, ChB, FRCP, FRACP
Director, Uppsala Monitoring Centre, Stora Torget 3, 753 20 Uppsala Sweden, ralph.edwards@who-umc.org

JOSIE M. M. EVANS, MA (Oxon) MPH, PhD
Lecturer in Epidemiology, Department of Epidemiology and Public Health, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK, j.m.m.stansfield@dundee.ac.uk

STEPHEN EVANS, BA, MSc, CStat, FRCP (Ed)
Professor of Pharmacoepidemiology, Medical Statistics Unit, The London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK, stephen.evans@lshtm.ac.uk
CONTRIBUTORS

RICHARD E. FERNER, MD, MSc, FRCP
Director, West Midlands Centre for Adverse Drug Reaction Reporting, City Hospital, Birmingham B18 7QH, UK, r.e.ferner@bham.ac.uk

JONATHAN A. FINKELSTEIN, MD, MPH
Associate Professor, Department of Ambulatory Care and Prevention and of Pediatrics, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA 02215, USA, Jonathan_Finkelstein@hphc.org

F. T. FRAUNFELDER, MD
Professor of Ophthalmology, Casey Eye Institute, Oregon Health Sciences University, 3375 SW Terwilliger Blvd, Portland, OR 97035, USA, fraunfel@ohsu.edu

F. W. FRAUNFELDER, MD
Assistant Professor, Cornea and External and Disease Director of the National Registry of Drug-Induced Ocular Side Effects, Casey Eye Institute, Oregon Health Sciences University, 3375 SW Terwilliger Blvd, Portland, OR 97035, USA, fraunfer@ohsu.edu

SIR CHARLES GEORGE, BSc, MD, FRCP
Medical Director, British Heart Foundation, 14 Fitzhardinge Street, London W1H 6DH, UK, cawdrong@bhf.org.uk

ALAN S. GO, MD, MPH
Physician Scientist, Division of Research, Kaiser Foundation Research Institute, Oakland, CA 94611, USA

MICHAEL J. GOODMAN, PhD
Senior Research Investigator, HealthPartners Research Foundation, Minneapolis, MN 55440, USA, Michael.J.Goodman@HealthPartners.com

DAVID J. GRAHAM, MD, MPH
Associate Director for Science and Medicine, Office of Drug Safety, Centre for Drug Evaluation and Research, US Food and Drug Administration, 5600 Fishers Lane, HFD-400, Rm 15B-32, Rockville MD 20857, USA, GRAHAM@CDER.FDA.GOV

A. C. VAN GROOTHEEST, MD
Director, Netherlands Pharmacovigilance Centre Lareb, Goudsloot vallei 7, 5273 MH’s-Hertogenbosch, The Netherlands, ac.vangroothoest@lareb.nl

THOMAS GROSS, MD, MPH
Director, Division of Postmarket Surveillance, Office of Surveillance and Biometrics, Center for Devices and Radiological Health, US Food and Drug Administration, 1350 Piccard Drive, Room 300P, Rockville, MD 20850, USA, TPG@CDRH.FDA.GOV

JERRY H. GURWITZ, MD
The Dr John Meyers Professor of Primary Care Medicine, University of Massachusetts Medical School and Executive Director, Meyers Primary Care Institute, Fallon Healthcare System, and University of Massachusetts Medical School, Worcester, MA 01605, USA

CHRISTOPH HILTL, Dr. jur.
Partner, Lovells Boesebeck Droste, Marshallstrasse 8, 80539 Munchen, Germany, christoph.hiltl@lovells.com

NORMA KELLETT, BSc, MBChB, MRCGP, FFPM
Director Clinical Services, Inveresk Research, Tranent EH33 2NE, UK, norma.kellett@inveresk.com

LARRY G. KESSLER, ScD
Office Director, Office of Surveillance and Biometrics, Center for Devices and Radiological Health, US Food and Drug Administration, 1350 Piccard Drive, Rockville MD 20850, USA lgk@cdrh.fda.gov

JUDITH L. KINMAN, MA
Project Manager, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, 824 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021, USA, jkinman@
CONTRIBUTORS

STEPHEN L. KLINCEWICZ, DO, MPH, JD
Global Safety Officer, Drug Safety and Surveillance, Johnson and Johnson Pharmaceutical Research and Development LLC, 1125 Trenton-Harbourtown Road, Titusville, NJ 08560-0200, USA, sklincew@prdus.jnj.com

CARMEN KREFT-JAIS, MD
Head, Pharmacovigilance Unit, Agence Francaise de Sécurité Sanitaire des Produits de Santé (AFSSAPS), 143/147 Bd Anatole France, 93 285 St Denis, France, carmen.kreft-jais@afssaps.sante.fr

PAOLA LA LICATA, JD
Lawyer, Lovells, Via Dei Due Marcelli 66, 00187 Roma, Italy, Paola.LaLicata@lovells.com

DAVID H. LAWSON, CBE, MD, FRCP
Head of Department of Clinical Pharmacology, Royal Infirmary, Glasgow, UK, ann.rodden@northglasgow.scot.nhs.uk

MARK D. LEARN, Esq.
Associate, Hogan & Hartson, L.L.P., Columbia Square, 555 Thirteenth Street, NW, Washington, DC 20004-1109, USA, MDLearn@HHLAW.com

MARIE LINDQUIST, MSc Pharm
Head of Data Management & Research, General Manager, Uppsala Monitoring Centre, Stora Torget 3, 753 20 Uppsala, Sweden, marie.lindquist@who-umc.org

THOMAS M. MACDONALD, BSc, MD, FRCP, FESC
Professor of Clinical Pharmacology and Pharmacoepidemiology, Director, MEdicines MOnitoring Unit (MEMO), Department of Clinical Pharmacology and Therapeutics, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK, tom@memo.dundee.ac.uk

NICHOLAS MACFARLANE, BA
Partner, Lovells, 65 Holborn Viaduct, London EC1A 2DY, UK, nicholas.macfarlane@lovells.com

STUART J. MAIR, MBChB, DRCOG, DCPSA
Medical Advisor, Inveresk Research, Tranent EH33 2NE, UK, stuart.mair@inveresk.com

PENELOPE K. MANASCO, MD
Chief Medical Officer, First Genetic Trust, 3 Parkway North Center Suite 150N, Deerfield, IL 60015, USA, pmanasco@firstgenetic.net

RONALD D. MANN, MD, FRCP, FRCGP, FFPM
Professor Emeritus, University of Southampton, UK, and 42 Hazleton Way, Waterlooville, Hampshire PO8 9BT, UK, DrMann@manorcottage.fsbusiness.co.uk

UNA MARTIN, BSc, PhD, FRCPI
Senior Lecturer in Clinical Pharmacology, Division of Medical Sciences, The University of Birmingham, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, UK, u.martin@bham.ac.uk

BRIAN C. MARTINSON, PhD
Research Investigator, HealthPartners Research Foundation, Minneapolis, MN 55440, USA, Brian.C.Martinson@HealthPartners.com

RONALD MEYBOOM, MD, PhD
Medical Adviser, Uppsala Monitoring Centre, Stora Torget 3, 753 20 Uppsala, Sweden, R.Meyboom@who-umc.org

CAROLINE MOORE, BA (Oxon)
Barrister, Lovells, 65 Holborn Viaduct, London EC1A 2DY, UK, caroline.moore@lovells.com

NICHOLAS MOORE, MD, PhD
Professor of Clinical Pharmacology, Département de Pharmacologie, Université Victor Segalen—CHU de Bordeaux, 33076 Bordeaux cedex, France, nicholas.moore@pharmaco.u-bordeaux2.fr
CONTRIBUTORS

MICHAEL MOSTELLER, MS, PhD  Statistical Geneticist, Population Genetics, Genetics Research, Glaxo SmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA, mm41601@gsk.com

WALTER S. NIMMO, BSc, MD, FRCP, FRCA, FANZCA, FFPM, FRSE  Chief Executive, Inveresk Research, Tranent EH33 2NE, UK, walter.nimmo@inveresk.com

STEN OLSSON, MSci, Pharm  Head, External Affairs, Uppsala Monitoring Center, Stora Torget 3, 753 20 Uppsala, Sweden, sten.olsson@who-umc.org

ROLAND ORRE, MSc  Department of Mathematical Statistics, Stockholm University S-10691 Stockholm, Sweden, orre@mathematic.su.se

B. KEVIN PARK, BSc (Hons), PhD, Hon MRCP  Professor of Pharmacology, Department of Pharmacology and Therapeutics, The University of Liverpool, Ashton Street, Liverpool L69 3GE, UK, bkpark@liverpool.ac.uk

TONI PIAZZA-HEPP, PharmD  Deputy Director, Division of Surveillance, Research and Communication Support, Office of Drug Safety, Center for Drug Evaluation and Research, US Food and Drug Administration, 5600 Fishers Lane, HFD-400, Rm 15B-32, Rockville, MD 20857, USA, PIAZZAHEPPT@ceder.fda.gov

GRAHAM A. PIPKIN, BSc (Hons)  Communications Manager, GI, Neurology and GI GCS, GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex UB11 1BU, UK, gp5771@gsk.com

MUNIR PIRMOHAMED, PhD, FRCP, FRCP (Ed)  Professor of Clinical Pharmacology/Consultant Physician, Department of Pharmacology and Therapeutics, The University of Liverpool, Ashton Street, Liverpool L69 3GE, UK, munirp@liv.ac.uk

RICHARD PLATT, MD, MSc  Professor of Ambulatory Care and Prevention, Harvard Medical School, Director of Research, Harvard Pilgrim Health Care, 133 Brookline Avenue, 6th Floor, Boston MA 02215, USA, richard.platt@channing.harvard.edu

E. P. VAN PUIJENBROEK, MD, PhD  Head, Science Department, Netherlands Pharmacovigilance Centre Lareb, Goudsloemvallei 7, 5273 MH’s-Hertogenbosch, The Netherlands, e.vanpuijenbroek@lareb.nl

MARSHA A. RAEBEL, PharmD  Pharmacotherapy Research Manager, Kaiser Permanente Colorado, and Adjoint Associate Professor of Pharmacy, University of Colorado School of Pharmacy, Denver, CO 80231, USA, Marsha.A.Raebel@kp.org

JUNE M. RAINIE, MA, MSc, FRCP (Ed)  Director, Post-Licensing Division, Medicines Control Agency, Market Towers, 1 Nine Elms Lane, London SW8 5NQ, UK, june.raine@mca.gov.uk

GAILE RENEGAR, JD, RPh  Director, Genetics Education and External Relations, Genetics Research, GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA, glr42379@gsk.com

PAOLO RICCI, JD  Partner, Lovells, Via Dei Due Marcelli 66, 00187 Roma, Italy, paolo.ricci@lovells.com

PATRICIA RIESER, BSN, RN, CFNP  Consultant, Genetics Education and External Relations, Genetics Research, GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA, pr63544@gsk.com